PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27725198-0	2016	Differential effect of rebamipide on transmembrane mucin biosynthesis in stratified ocular surface epithelial cells.	rebamipide	23-33	LOC100508689	Homo sapiens	51-56	
33232357-0	2020	Assessment of mucin-related gene alterations following treatment with rebamipide ophthalmic suspension in Sjogren"s syndrome-associated dry eyes.	rebamipide	70-80	LOC100508689	Homo sapiens	14-19	
33232357-3	2020	In addition, we investigated alterations in mucin-related gene expression secondary to treatment with rebamipide ophthalmic suspension in patients with Sjogren"s syndrome-associated dry eyes (SS-DE).	rebamipide	102-112	LOC100508689	Homo sapiens	44-49	
28587435-1	2017	It has been demonstrated that topical administration of rebamipide, which is an antiulcer agent, increases the mucin level of the tear film and ameliorates ocular surface conditions such as lid wiper epitheliopathy.	rebamipide	56-66	LOC100508689	Homo sapiens	111-116	
22335446-10	2012	CONCLUSIONS: Rebamipide promoted glycoconjugate, which has a property as a mucin-like glycoprotein, in human corneal epithelial cells.	rebamipide	13-23	LOC100508689	Homo sapiens	75-80	
22969286-3	2012	The therapeutic effects of rebamipide eye drops are due to its ability to increase corneal and conjunctival mucin-like substances and improve corneal and conjunctival injury in vivo.	rebamipide	27-37	LOC100508689	Homo sapiens	108-113	
18975081-6	2009	Total gastric mucin output was significantly increased by 53% by rebamipide administration from 3.2 +/- 1.2 mg hexose/10 min to 4.9 +/- 2.2 mg hexose/10 min (P < 0.01).	rebamipide	65-75	LOC100508689	Homo sapiens	14-19	
18975081-7	2009	Further analysis by ion-exchange chromatography revealed that rebamipide administration induced a specific increase in acidic mucin rich in sialic acid.	rebamipide	62-72	LOC100508689	Homo sapiens	126-131	
35184054-10	2022	Adding either exogenous mucin or the mucin secretagogue, rebamipide, partially alleviated the PSL-induced dysbiosis of the gut microbiota.	rebamipide	57-67	LOC100508689	Homo sapiens	37-42	
28983630-3	2017	The present study investigated whether rebamipide (Reb) acts as a secretagogue of intestinal mucin and the underlying mechanisms involved, thereby focusing on the effect on goblet cells.	rebamipide	39-49	LOC100508689	Homo sapiens	93-98	
28458352-7	2017	The administration of this ultrafine rebamipide suspension (2%) increased the conjunctival mucin, which was comparable to the commercially available micro-particle suspension (2%).	rebamipide	37-47	LOC100508689	Homo sapiens	91-96	
27257394-1	2016	OBJECTIVE: Rebamipide ophthalmic suspension was developed for the treatment of dry eyes and for other corneal diseases, promoting the secretion of both mucin in tear fluid and membrane-associated mucin, increasing the number of goblet cells, and restoring the barrier function of the corneal epithelium.	rebamipide	11-21	LOC100508689	Homo sapiens	152-157	
27257394-1	2016	OBJECTIVE: Rebamipide ophthalmic suspension was developed for the treatment of dry eyes and for other corneal diseases, promoting the secretion of both mucin in tear fluid and membrane-associated mucin, increasing the number of goblet cells, and restoring the barrier function of the corneal epithelium.	rebamipide	11-21	LOC100508689	Homo sapiens	196-201	
24204116-1	2013	Administration of topical rebamipide increases the mucin level of tear film and improves the ocular surface in short break-up time type of dry eye.	rebamipide	26-36	LOC100508689	Homo sapiens	51-56	
25574215-1	2015	The topical administration of rebamipide (Mucosta ), an antiulcer agent, clinically increases the mucin level of tear film.	rebamipide	30-40	LOC100508689	Homo sapiens	98-103	
25574215-7	2015	By contrast, the secondary resected specimen obtained three months after the initiation of topical rebamipide treatment revealed the epithelium and nevus, where numerous goblet cells were present (28 cells/HPF), and mucin-like substances were markedly secreted from the goblet cells.	rebamipide	99-109	LOC100508689	Homo sapiens	216-221	
24940041-3	2014	Investigations have confirmed that rebamipide increases corneal and conjunctival mucin-like substances along with improving corneal and conjunctival injury.	rebamipide	35-45	LOC100508689	Homo sapiens	81-86	
24940041-4	2014	Clinically, rebamipide ophthalmic suspensions can effectively treat tear deficiency and mucin-caused corneal epithelial damage, and can restore the microstructure responsible for tear stability.	rebamipide	12-22	LOC100508689	Homo sapiens	88-93	
23662915-3	2013	The eyedrop form of rebamipide, approved in Japan for use in the treatment of dry eye diseases, upregulates mucin secretion and production, thereby suppressing superficial punctate keratopathy on the ocular surface of patients with this disease.	rebamipide	20-30	LOC100508689	Homo sapiens	108-113	
27194990-5	2016	Subjective symptoms and expression levels of ocular surface mucin improved after combined treatment of rebamipide (4 times daily) and fluorometholone (once daily) ophthalmic suspension.	rebamipide	103-113	LOC100508689	Homo sapiens	60-65	
27194990-8	2016	Subjective symptoms and expression levels of ocular surface mucin improved by combined treatment of rebamipide (4 times daily) and fluorometholone (once daily) ophthalmic suspension.	rebamipide	100-110	LOC100508689	Homo sapiens	60-65